Vir Biotechnology Inc (VIR)

Viral Hepatitis · registered primary completion 2026-12-01 · NCT07128550

Published 2026-09-02Market cap $1,833M7 sourced statements

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide · PHASE3 · n=150 · active not recruiting

Market

fact

No approved product carries Viral Hepatitis on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT07128550: randomized, open-label, 150 participants (estimated). Primary outcome: HDV RNA < Lower Limit of Quantification (LLOQ), Target not detected (TND) at Week 24. 1 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Runway

fact

Cash of $529M against operating outflow of $88M per quarter gives roughly 6.0 quarters of runway, clearing the registered primary completion 1.1 quarters out by 4.9 quarters.

Source: 10-Q filed 2026-08-05

Share count and dilution

fact

169,215,958 shares outstanding against 179,589,293 if every outstanding option, warrant and convertible were exercised. In that case 5.8% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-05

Regulatory

fact

Designations disclosed: Breakthrough Therapy, Fast Track, Orphan Drug, PRIME (EU). These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-05

Pipeline

fact

7 distinct molecules in 7 active company-sponsored trials; Tobevibart accounts for 3 of them at Phase 2/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 2.9%.

Source: DEF 14A filed 2026-04-16

Don't see a name? Request a sheet. Any US-listed biotech with a Phase 3 or a pending FDA decision — it gets built the same way, from the filings.

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.